What is HLH, and what role did it play in the death of a healthy 34-year-old ESPN reporter? – 11Alive.com WXIA

ATLANTA How does a healthy 34-year-old die after being diagnosed with pneumonia?

That's the question at the heart of the tragic and sudden death of an ESPN reporter earlier this week.

According to college football reporter Edward Aschoff's fiance, Katy Berteau, about a week after being diagnosed with a severe form of pneumonia, he began treatment for a "presumed diagnosed" of hemophagocytic lymphohistiocytosis (HLH). Three days after being moved to the ICU, Berteau tweeted from Aschoff's account on Thursday night, he died.

RELATED: Edward Aschoff's fiance releases new information about ESPN reporter's sudden death, memorable life

HLH is a rare and complicated condition that's not entirely well-understood by researchers, but it basically stems from your immune system severely overreacting to an infection (such as pneumonia) or another illness.

"It just gets overworked and starts fighting regular tissues, so usually those tissues are organs, like your spleen or your liver," Atlanta area doctor Will Epps said. "So it can result in liver failure or organ failure and unfortunately end up expiring from it."

Here's a general outline:

According to the Genetic and Rare Diseases Information Center at the National Institutes of Health, HLH comes in two forms: A genetic form and an acquired form.

St. Jude Children's Research Hospital says the genetic form is more common in young children, while the acquired form, sometimes called the secondary form, usually affects older children and adults, such as Aschoff.

What happens, broadly, is this: Faced with a severe infection, such as pneumonia (or other severe conditions like cancer), a person's immune system overreacts and, as the Johns Hopkins School of Medicine describes it, certain while blood cells called histiocytes and lymphocytes "attack your other blood cells."

"These abnormal blood cells collect in your spleen and liver, causing these organs to enlarge," Johns Hopkins says.

(According to the NIH, HLH may also be associated with a separate genetic condition X-linked lymphoproliferative disease - XLP - when it results from an inappropriate immune response.)

It can cause death in a matter of weeks, according to researchers.

A 2012 paper in the medical journal "Clinical Advances in Hematology & Oncology,"outlines adult HLH extensively.

"It is useful to think of HLH as the severe end of a spectrum of hyperinflammatory diseases in which the immune system causes damage to host tissues," the paper's authors, Dr. Roman Leonid Kleynberg and Dr Gary J. Schiller, wrote.

That paper estimated HLH occurs in only 1.2 cases per one million individuals every year, making it extremely rare.

Specifically amongst children, St. Jude estimates HLH is diagnosed in fewer than 1 out of every 50,000 - 100,000 children per year.

The condition's mortality rate is difficult to pin down because it can fluctuate based on what caused it. Many sources say a common cause is Epstein-Barr virus, for example, and the 2012 paper reported the mortality rate associated with that 18-24 percent. Other causes can have lower mortality rates.

Generally, doctors try both to treat the underlying trigger for HLH and address the immune response.

"Treating that is tamping that down, either through steroids or with a chemotherapeutic agent which tends to attack or lower that immune system," Epps said.

John Hopkins Medicine also details antibiotic and antiviral drugs being used, or if drug treatment fails doctors may turn to stem cell transplants.

There is no known way to prevent HLH.

MORE HEADLINES

Sophie's Nightmare: How a Georgia mother allowed her boyfriend to impregnate her 10-year-old

'They were sitting on the couch together ... and out of nowhere they were murdered'

Man tortured by gang members, skull 'depressed' in one the most brutal murders in Atlanta

Read the original:
What is HLH, and what role did it play in the death of a healthy 34-year-old ESPN reporter? - 11Alive.com WXIA

New technology being used to heal serious wounds – WWLTV.com

NEW ORLEANS Nancy Van Den Akker went through a difficult time.

Compressed discs caused pain shooting down her leg. In May, she had surgery to fix that. Then there was another problem.

"Was about ready to start physical therapy when apparently some of the stitches in the side opened up. I had kind of these gaping holes there," said Nancy Van Den Akker.

It's harder for diabetics like Nancy to heal, so even with standard wound medicine the incision stayed open for three months. Then Tulane reconstructive plastic surgeon Dr. Abigail Chaffin asked Nancy to try new technology.

"What we're talking about today is living tissue. These are donated placentas from healthy mothers, undergoing planned C-sections, that give consent to donate tissue that would otherwise be discarded," explained Dr. Abigail Chaffin, a reconstructive plastic surgeon specializing in wound medicine who is the Medical Director of the MedCentris Wound Healing Institute at Tulane.

The tissue comes in many sizes. Dr. Chaffin spreads it out over the wound, then it's bandaged for a week. The tissue bathes the wound in growth factors and stem cells helping regenerate your own tissue, faster.

"These can be used for many different type of wounds, from diabetic ulcers, venous ulcers, non-healing surgical wounds, over any area of the body," said Dr. Chaffin.

This can keep people out of the operating room with anesthesia and from having a painful skin graft that leaves a big scar. It can also help prevent infection and limb amputation. She even used it successfully before surgery on a young patient whose wound did not heal for 10 years.

Nancy healed in four weeks with the treatment.

"It's all healed up. I don't even feel it. Within just a couple of weeks, I was able to start physical therapy," said Nancy Van Den Akker.

Every time someone is finished with the treatment the medical team rings a big bell hanging in the center.

Now that her medical team has declared Nancy healed, she can't wait to take the senior dog she rescued out for walks again.

Here are more before and after pictures:

The MedCentris Wound Healing Institute is doing a study at Tulane on the effectiveness of the new technology.

It's for any child or adult who has an open wound for at least four weeks.It is through your insurance and co-pay.

For more call 504-399-3605 or toll free, 1-855-HEAL-DAT.

Get breaking news from your neighborhood delivered directly to you by downloading the new FREE WWL-TV News app now in theIOS App StoreorGoogle Play.

Read the original here:
New technology being used to heal serious wounds - WWLTV.com

Five hot topics in autism research in 2019 – Spectrum

This year, researchers unearthed clues to the causes of autism and how to treat it from a variety of sources.

Advances in tiny models of the human brain bared new details about the biology of autism and provided possible platforms for testing therapies. Studies of heart rate put a spotlight on the autonomic nervous system as a potential wellspring of autism traits. And others forged a controversial connection between the gut microbiome and autism.

A few studies revealed important information about the time points at which different forms of autism are amenable to therapy. This year also saw scrutiny of tests used for screening and diagnosis, revealing gaps and limitations in the system for identifying autistic children.

Here are the years top five topics in autism research.

Brain organoids start as mere clusters of stem cells, which then are coaxed to mature into brain cells. This year, the life span of these brains-in-a-dish grew to one year and then nearly two, enabling them to mature and mimic some aspects of the human brain. In the longest-lived organoids, researchers tracked changes in the expression of autism genes. Organoids derived from the skin cells of autistic people have a shortage of cells that suppress brain activity, they found. The finding supports the signaling imbalance theory of autism, which holds that the brains of autistic people are hyper-excitable.

This year, scientists also built tiny replicas of two brain areas bridged by a long fiber tract that might reveal how long-range connections are altered in the brains of people with autism.

Brain organoids spun from people with fragile X syndrome may help explain why some experimental fragile X drugs work in mice but not in people and generate leads for effective therapies. Organoids could provide a platform for testing treatments, too, as researchers can now churn out hundreds of these brain-like blobs in parallel and make them uniform in shape and composition.

More distant applications include studies of consciousness and the effects of microgravity on the brain. In a fledgling sign of the former, brain organoids showed synchronized neuronal firing patterns, some aspects of which look like those in preterm infants.

New evidence emerged tying autism to the workings of the autonomic nervous system, which controls breathing, heart rate and digestion. Differences in the system could explain a range of autism traits, including social difficulties and sensory sensitivity, as well as heart problems and digestive issues.

Many of these differences show up in the heart rate. Heart rate remains steady in autistic people as they breathe instead of the typical pattern of slowing slightly on exhale and quickening on inhale. This discrepancy arises after 18 months of age, around the same time that the conditions core traits emerge. Children with Rett syndrome also have unusual heart-rate patterns.

These differences may persist beyond childhood. One study showed that autistic adults resting heart rates rarely vary; an even heart rate suggests a lack of flexibility in responding to environmental changes.

Autistic children are unusually prone to gastrointestinal problems. This association may not be a coincidence: Certain genetic mutations or alterations in the microbiome the mix of microbes in the intestines may contribute to both autism and gut problems.

Four mouse studies in 2019 offered up fresh evidence some of it controversial to support this idea. In one study, researchers replaced the gut microbes in mice with those from autistic boys. The mice have repetitive behaviors, make fewer vocalizations and spend less time socializing than controls do, providing the first evidence that gut microbes contribute to autism traits.

But within hours of the studys publication, several experts criticized its small sample size and highly variable results. Others found a possible statistical error.

In an unrelated study, researchers revealed that oral doses of Lactobacillus reuteri, a type of gut bacteria found in yogurt and breast milk, boost social behavior in three mouse models of autism. And two other sets of findings suggested that mutations in NLGN3, a high-confidence autism gene, alter gut function. One of them showed that a mutation in this gene disrupts the mices microbiome.

Drugs for autism may be most effective when given during a critical period of brain development. Researchers delineated the windows for treating autism traits in mouse and rat models of the condition.

One study revealed that by the time mice reach adulthood, they have lost their ability to learn from social experiences. Giving adult mice an injection of 3,4-methylenedioxymethamphetamine (MDMA), the active ingredient in ecstasy, reopens the critical window for learning.

In another study, researchers fed the cholesterol drug lovastatin to rat models of fragile X syndrome. The treatment, if given at 4 weeks of age (the rat equivalent of childhood), prevents cognitive problems, the researchers found.

The timing of treatments may be more important for some forms of autism than for others. A study of mice missing UBE3A, the gene mutated in Angelman syndrome, showed that the earlier in life the gene is restored, the more the mice improve.

By contrast, a mutation in the autism gene SCN2A has many of the same effects on neurons when introduced into adolescent mice as it does when it is present from conception. And unpublished results show that correcting an SCN2A mutation in adulthood reverses these problems.

A series of studies this year called into question the accuracy of early screening and revealed racial disparities in autism diagnoses.

Some studies cast doubt on the utility of a widely used screening tool, the Modified Checklist for Autism in Toddlers: The test identifies less than 40 percent of autistic children, and 85 percent of those it does flag do not have autism.

Of the toddlers the test flags, most do not receive follow-up evaluations. And for those who are seen again, a definitive diagnosis may not be possible right away. Some children who screen negative at age 3 meet the diagnostic criteria for autism only after age 5.

Not all children have equal access to autism evaluations, with black and Hispanic children at a disadvantage in several U.S. states. In New Jersey, black children are half as likely as white children to receive an autism assessment by age 3.

About 9 percent of autistic children may outgrow an autism diagnosis but still have other conditions that require support, highlighting the need for continued observation to adapt to their evolving needs.

See original here:
Five hot topics in autism research in 2019 - Spectrum

Humans may be Able to Regrow Teeth in the Future – NullTX

Scientific developments can have a major impact on society. It now appears that human teeth can simply be regrown through a relatively simple medical procedure.

When an adult human loses a tooth, it will never come back.

The only option to fill the gap is by using a fake tooth, or implant.

Unfortunately, those problems only grow bigger as humans grow older.

Addressing the loss of teeth has proven challenging, albeit a solution may have been discovered.

Gaining the ability to regrow teeth would certainly be beneficial to society as a whole.

Research into this matter is underway, resulting in some promising options to explore.

It appears the patients own stem cells can be used to regrow lost or damaged teeth.

That is the working theory, at least, as human trials have not been conducted yet.

When human trials will officially begin, has not been announced at this time.

A lot more research and development is needed to deem such trials safe.

Until then, tooth loss will need to be remedied with implants.

That solution has worked well for several decades, as they can serve as genuine teeth.

The downside is how the healing process associated with implants is rather lengthy, and the costs remain relatively high.

Link:
Humans may be Able to Regrow Teeth in the Future - NullTX

Gene Therapy Market 2019-2027 / Trends, Growth, Opportunities And Top Key – Market Research Sheets

The report covers the forecast and analysis of the gene therapy market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the gene therapy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the gene therapy market on a global level.

In order to give the users of this report a comprehensive view of the gene therapy market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are bench marked based on their market size, growth rate, and general attractiveness.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10170423

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new service launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the gene therapy market by segmenting the market based on the type, vector type, therapy area, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Gene therapy is utilized for treating neurodegenerative disorders like Alzheimer, amyotrophic lateral sclerosis, and spinal muscular atrophy. Gene therapy is one of the key treatment kinds that will propel the market growth over the forecast period. Moreover, gene therapy also finds lucrative applications in precision medicine. In addition to this, a rise in the occurrence of cancer is prompting the demand to treat the disease through gene therapy.

Based on the type, the market can be segregated into Germ Line Gene Therapy and Somatic Gene Therapy. In terms of vector type, the gene therapy industry can be divided into Viral Vectors, Non-Viral Vectors, and Human Artificial Chromosome. On the basis of therapy area, the market for gene therapy can be classified into Cancer, Neurological Diseases, Infectious Diseases, Genetic Disorders, Rheumatoid Arthritis, and Others.

Request For Full Report:https://www.kennethresearch.com/sample-request-10170423

The key players included in this market are Advanced Cell & Gene Therapy, Audentes Therapeutics, Benitec Biopharma, Biogen, Blubird Bio, Inc., Bristol-Myers Squibb Company, CHIESI Farmaceutici SPA, Eurofins Scientific, Geneta Science, Genzyme Corporation, Gilead, GlaxoSmithKline PLC, Human Stem Cells institute, Novartis AG, Orchard Therapeutics, Pfizer Inc., Sangamo therapeutics, Spark therapeutics, and Voyager Therapeutics.

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

This post was originally published on Market Research Sheets

Read this article:
Gene Therapy Market 2019-2027 / Trends, Growth, Opportunities And Top Key - Market Research Sheets

AgeX Therapeutics Announces Drawdown of Second Tranche of Loan Facility from Juvenescence Ltd. – BioSpace

Juvenescence is pleased to continue its commitment to AgeX through this additional drawdown under the loan facility, commented Gregory Bailey, MD, Chairman of AgeX and CEO of Juvenescence. Juvenescence remains committed to funding the future development plans of AgeX through further advancements under the loan facility or otherwise. Since Juvenescences initial investment in AgeX in June 2018, AgeX has been an important element in the Juvenescence mission and strategy. Juvenescence is also investing its time and personnel to support AgeXs business development initiatives which have impressive potential. We look forward to AgeX announcing its plans for 2020 as it pursues tissue regeneration in Reverse Bioengineering, while advancing the development of BAT and VASC 1, the coupling of HLA-G with PureStem-derived cells for transplant therapies, and exploring partnerships with third parties.

This round of funding will allow us to continue to execute on our strategic plan to provide therapies for certain chronic and degenerative diseases through cellular regeneration and replacement, commented AgeXs founder and CEO Michael D. West, PhD.

As announced in the companys news release on August 14, 2019, AgeX has obtained a $2 million credit facility from Juvenescence to finance AgeXs operations and advance its product development programs.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191226005045/en/

Visit link:
AgeX Therapeutics Announces Drawdown of Second Tranche of Loan Facility from Juvenescence Ltd. - BioSpace

ESPN reporter diagnosed with pneumonia, HLH. What is HLH? – KXLY Spokane

Edward Aschoff, a college football reporter for ESPN, died Tuesday on his 34th birthday, according to ESPN Edward Aschoff, a college football reporter for ESPN, died Tuesday on his 34th birthday, according to ESPN Related stories

BRISTOL, Conn. - When ESPN reporter Edward Aschoff died, he had been diagnosed with multifocal pneumonia and a rare disease known as HLH, his fiance tweeted.

Aschoff was first admitted to the hospital and diagnosed with pneumonia in many parts of his lungs but was brought back to the emergency room when antibiotic treatment failed and he got worse, Katy Berteau said.

"After many tests - bone marrow and lung biopsies - treatment was started for a presumed diagnosis of HLH," she tweeted. "Within 3 days of being moved into the ICU, he passed."

HLH, hemophagocytic lymphohistiocytosis, is a rare disease that affects the immune system.

She did not provide any further details about the manner of Aschoff's death, which occurred on his 34th birthday.

Other people, including Aschoff himself, expressed surprise about the seriousness of the illness in a young man in apparently good health.

"Anyone ever had multifocal (bilateral) pneumonia in their early 30s as some who never gets sick and has a very good immune system? Asking for two friends ... my lungs," he tweeted on December 5.

More questions have come up about his second diagnosis, HLH. It is unclear if Aschoff had HLH or pneumonia first, if one came from the other, and exactly how he died so quickly.

Here is what we know about the diseases Aschoff's had:

Pneumonia is when air sacs in the lungs fill with fluid or pus. It can be caused by a virus, bacteria or a fungus, causing a fever and respiratory problems.

It can occur in one or both lungs, and multifocal means the pneumonia occurs in multiple places.

Thousands of people die around the world each year of pneumonia, but most healthy people can fight it off, especially with antibiotics and antiviral medications. The people most at risk are the young, elderly, frail or immune-compromised.

HLH is a rare disease that affects the immune system, making certain white blood cells attack other blood cells and enlarging the spleen and liver, according to Johns Hopkins Medicine.

It can be inherited or acquired, Johns Hopkins said. About a quarter of cases are passed down through families, and the rest come from infections, a weakened immune system and cancer.

Symptoms can include coughing, difficulty breathing, fever, headaches, rashes, swollen lymph nodes, jaundice and digestive problems, according to Johns Hopkins.

There is treatment for HLH, and acquired forms may clear when properly treated, Johns Hopkins said. If familial HLH goes untreated, it is usually fatal.

Treatments include chemotherapy, immunotherapy, steroids, antibiotic drugs and antiviral drugs. Stem cell transplants can cure HLH in most cases if drug treatments don't work, Johns Hopkins said.

There is no way to prevent HLH, the medical center said.

Read this article:
ESPN reporter diagnosed with pneumonia, HLH. What is HLH? - KXLY Spokane

Top Providers of the Alpha Thalassemia Market gives a New Dimension easing Measurement and Quantification – GuruFocus.com

Inclusive study on Alpha Thalassemia Market to Attractive Growth by Strategic Industry Evolutionary Analysis 2029| Segmentation, Future Scope, Development Strategies, Competitive Breakdown, and Regional Forecast. The market is expected to remain prominent in the Asia Pacific, Center East, and Africa, North America, South America, and Europe regions as companies are intensifying business operations and focusing on increasing market share.

Explosive Growth In Alpha Thalassemia Market size in terms of revenue (USD MN) is calculated for the study along with the aspects of the factors affecting the market growth (drivers and restraints). The market for alpha thalassemia has been categorized into various segments, for analysis, on the basis of the type, application area, and region. Detailed analysis of alpha thalassemia market Predicted to grow by 2029 with competitive Analysis identifying the key mutual trends and major players of the market and business guidelines till 2029. This strong growth outlook of the Alpha Thalassemia market has been attributed to the advancements in computing capacity for Alpha Thalassemia-based research and applications.

Furthermore, the report offers an in-depth understanding of alpha thalassemia market-particular drivers, constraints and major micro markets. The report highlights many significant points and trends of the industry which are helpful for our esteemed clients. In this research study, the manufacturing base, productivity, manufacturers, strengths, recent trends, features are identified in detailed.

*******Super Discount!! Grab Maximum up-to 25% off On Our Market Research Reports [Single User | Multi User| Corporate Users] Valid Till 31st December 2019.*******

To get all-inclusive information on forecast analysis of the market, request a Free PDF brochure here: https://market.us/report/alpha-thalassemia-market/request-sample/

[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology]

About Alpha Thalassemia Industry

As per the findings of a new Market.us report titled,Global Alpha Thalassemia Market By Type (Iron Chelating Drugs, Gene Therapy),By Application (Hospitals, Private clinics) and by Region Global Forecast to 2029.This offers a holistic view of the alpha thalassemia market through systematic segmentation that covers every aspect of the target market. The study provides valued information on key competition trends and the most preferred developmental strategies of leading market brands. The analysis covers alpha thalassemia market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the alpha thalassemia industry across sections such as also application and representatives.

Additionally, the analysis also has a comprehensive review of the crucial players on the alpha thalassemia market together side their company profiles, SWOT analysis, latest advancements, and business plans.

Get a customized report here: https://market.us/report/alpha-thalassemia-market/#inquiry

For the Alpha Thalassemia Market research study, the following years have been considered to estimate the market size:

Historic Year:2012 to 2018

Estimated Year:2019

Forecast Year:2020 to 2029

The Alpha Thalassemia Market report serves as a vital guide in portraying present and forecast industry statistics

-The supply/ demand situation, gross margin view and competitive profile of top Alpha Thalassemia players (Bluebird Bio, Novartis, Kiadis Pharma) are presented.

-The Alpha Thalassemia market breakdown by product, type, application and regions will provide sophisticated and precise analysis. Recent developments in Alpha Thalassemia industry, growth opportunities, constraints are studied completely.

-The revenue estimates of Alpha Thalassemia market based on top industry players, their product type, applications and regions is studied.

-In the next segment, the SWOT analysis of players, cost structures, traders, distributors and dealers are listed.

-The forecast study on Alpha Thalassemia industry will be useful for business plans and growth analysis.

-This document is a helpful source of guidance for anyone interested in investing in the Brazing Materials Sale, Insights industry. We welcome requests for any special requirements or customizations from our clients.

To Get Immediate Access, Invest On Report Here: https://market.us/purchase-report/?report_id=66566

Explore More Trending Research Reports Here:

Endoscopy Baskets Market Growth Potential, Opportunities, Industry Challenges and Risks 2029

Drug Allergy Treatments and Drugs Market (2020-2029) Trends and Top Key Companies Profile | Allergy Therapeutics, HAL Allergy Group and Stallergenes Greer

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at [emailprotected].

WiredRelease

Visit WiredRelease's Website

Excerpt from:
Top Providers of the Alpha Thalassemia Market gives a New Dimension easing Measurement and Quantification - GuruFocus.com

Lip Augmentation Market Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2027 | Allergan, Anika Therapeutics, Cytophil -…

Lip augmentation is a type of procedure that aims to increase the fullness of a lip through enlargement using fillers such as hyaluronic acid, fat, or implants. Lip augmentation is a cosmetic procedure that gives filled, plumper lips. Nowadays, injectable dermal filler is the most commonly used method of lip augmentation. There are many dermal fillers that can be injected in your lips and around your mouth. The lip augmentation market is anticipated to grow in the market by rising participation of market players and the development of the medical tourism industry. Whereas increasing awareness about lip augmentation is rising geriatric population, and rising demand for dermal fillers is expected to grow the market in the forecast period. However, side effects cause by lip fillers, and high cost of treatment is restraining the market growth.

Download Exclusive PDF Sample [emailprotected] https://www.reportsweb.com/inquiry&RW00013057619/sample

Top Manufacturers Profiles Operating in this Study:

Allergan Anika Therapeutics Inc. Cytophil, Inc. Galderma Laboratories, L.P. Informa plc. Integra LifeSciences Corporation Korman Laboratories Merz Pharma GmbH & Co.KGaA Suneva Medical, Inc Teoxane

MARKET SCOPE

The Lip Augmentation Market Analysis to 2027 is a specialized and in-depth study of the medical devices industry with a special focus on the global market trend analysis. The report aims to provide an overview of in lip augmentation market with detailed market segmentation by type, lip fillers, distribution channel and geography. The lip augmentation market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading in lip augmentation market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The lip augmentation market is segmented on the basis of type, lip fillers, distribution channel. Based on type the market is segmented as temporary lip augmentation and permanent lip augmentation. On the basis of lip fillers the market is categorized as fat injection or lipoinjection, hyaluronic acid fillers, lip collagen injections, platelet-rich plasma (PRP) and others. On the basis of distribution channel the market is categorized as hospital pharmacies, clinics, retail pharmacies, drug stores, online pharmacies and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the in lip augmentation market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The lip augmentation market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting lip augmentation market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the lip augmentation market in these regions.

Avail [emailprotected] https://www.reportsweb.com/inquiry&RW00013057619/discount

TABLE OF CONTENTS

1. INTRODUCTION1.1. SCOPE OF THE STUDY1.2. PUBLISHER RESEARCH REPORT GUIDANCE1.3. MARKET SEGMENTATION1.3.1 Lip Augmentation Market By Type1.3.2 Lip Augmentation Market By Lip fillers1.3.3 Lip Augmentation Market By Distribution Channel1.3.4 Lip Augmentation Market By Region1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. LIP AUGMENTATION MARKET LANDSCAPE4.1. OVERVIEW4.2. PEST ANALYSIS4.2.1 North America Pest Analysis4.2.2 Europe Pest Analysis4.2.3 Asia-Pacific Pest Analysis4.2.4 Middle East and Africa Pest Analysis4.2.5 South and Central America Pest Analysis4.3. EXPERT OPINIONS

Continue..

About ReportsWeb:

ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:

Call: +1-646-491-9876Email: [emailprotected]

This post was originally published on Market Reports Observer

Read more:
Lip Augmentation Market Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2027 | Allergan, Anika Therapeutics, Cytophil -...

ESPN reporter diagnosed with pneumonia, HLH. What is HLH? – Crossroads Today

Edward Aschoff, a college football reporter for ESPN, died Tuesday on his 34th birthday, according to ESPN Edward Aschoff, a college football reporter for ESPN, died Tuesday on his 34th birthday, according to ESPN Related stories

BRISTOL, Conn. - When ESPN reporter Edward Aschoff died, he had been diagnosed with multifocal pneumonia and a rare disease known as HLH, his fiance tweeted.

Aschoff was first admitted to the hospital and diagnosed with pneumonia in many parts of his lungs but was brought back to the emergency room when antibiotic treatment failed and he got worse, Katy Berteau said.

"After many tests - bone marrow and lung biopsies - treatment was started for a presumed diagnosis of HLH," she tweeted. "Within 3 days of being moved into the ICU, he passed."

HLH, hemophagocytic lymphohistiocytosis, is a rare disease that affects the immune system.

She did not provide any further details about the manner of Aschoff's death, which occurred on his 34th birthday.

Other people, including Aschoff himself, expressed surprise about the seriousness of the illness in a young man in apparently good health.

"Anyone ever had multifocal (bilateral) pneumonia in their early 30s as some who never gets sick and has a very good immune system? Asking for two friends ... my lungs," he tweeted on December 5.

More questions have come up about his second diagnosis, HLH. It is unclear if Aschoff had HLH or pneumonia first, if one came from the other, and exactly how he died so quickly.

Here is what we know about the diseases Aschoff's had:

Pneumonia is when air sacs in the lungs fill with fluid or pus. It can be caused by a virus, bacteria or a fungus, causing a fever and respiratory problems.

It can occur in one or both lungs, and multifocal means the pneumonia occurs in multiple places.

Thousands of people die around the world each year of pneumonia, but most healthy people can fight it off, especially with antibiotics and antiviral medications. The people most at risk are the young, elderly, frail or immune-compromised.

HLH is a rare disease that affects the immune system, making certain white blood cells attack other blood cells and enlarging the spleen and liver, according to Johns Hopkins Medicine.

It can be inherited or acquired, Johns Hopkins said. About a quarter of cases are passed down through families, and the rest come from infections, a weakened immune system and cancer.

Symptoms can include coughing, difficulty breathing, fever, headaches, rashes, swollen lymph nodes, jaundice and digestive problems, according to Johns Hopkins.

There is treatment for HLH, and acquired forms may clear when properly treated, Johns Hopkins said. If familial HLH goes untreated, it is usually fatal.

Treatments include chemotherapy, immunotherapy, steroids, antibiotic drugs and antiviral drugs. Stem cell transplants can cure HLH in most cases if drug treatments don't work, Johns Hopkins said.

There is no way to prevent HLH, the medical center said.

Here is the original post:
ESPN reporter diagnosed with pneumonia, HLH. What is HLH? - Crossroads Today